Safety Update – product information updates

When new safety information comes to light about medicinal products, Swissmedic works closely with marketing authorisation holders to update the corresponding product information (Information for healthcare professionals and Patient information). As a result, healthcare professionals gain timely access to safety-related findings.

The following overview is updated monthly and provides information about selected active substances or active substance groups whose Information for healthcare professionals has been, or will be, updated with new safety-related information.

These updates are currently available in German, French, or Italian.

Important information

The updates to product information for generics are delayed as these are adapted at a later date to those of the original product. Please note that this is not a complete overview since not all changes to individual Information for healthcare professionals are presented in detail, and the safety information listed for individual medicinal products containing an active substance or substance class may already be included in the Information for healthcare professionals.

The information is subject to possible legal remedies. In all cases, the current versions of the Information for healthcare professionals available at www.swissmedicinfo-pro.ch are binding.

All Safety Updates since November 2025

Safety of medicines – always up to date

Subscribe to the newsletter

The “Safety of medicines” newsletter provides monthly updates on the most important revisions to the product information for selected active substances or substance groups.

November 2026

Active substance(s) New safety information Updated section(s) (D)HPC
Aflibercept Reactions due to intravitreal injections (e.g. retinal tear, traumatic cataract, retinal vasculitis with/without occlusion), immunogenicity: Patients should be informed of the symptoms of ocular complications and encouraged to report them immediately. Warnings and precautions; Undesirable effects –
Aflibercept Increased intraocular pressure: The injection must not be performed while the intraocular pressure is ≥ 30 mmHg. Warnings and precautions –
Aflibercept Bilateral treatment: The risk of systemic adverse events may be increased. Warnings and precautions –
Aflibercept Concomitant use of other anti-VEGF agents: Limited experience with concomitant systemic or ocular treatment with other anti-VEGF agents Warnings and precautions –
Aflibercept Suspend treatment in the event of significant loss of visual acuity or ocular complications. Warnings and precautions –
Aflibercept Retinal pigment epithelium tear: Increased risk with extensive and/or severe detachments of the retinal pigment epithelium. Caution is advised in these patients. Warnings and precautions –
Alectinib Severe hypertriglyceridemia with resulting acute pancreatitis: blood triglyceride monitoring; discontinue treatment if occurs Dosage/use; Warnings and precautions; Undesirable effects DHPC – Alecensa® (Alectinib)
Dabrafenib Potentiation of radiation damage Warnings and precautions; Undesirable effects –
Galantamine Nightmares Undesirable effects –
GLP-1 receptor agonists Necrotising pancreatitis Warnings and precautions; Undesirable effects –
Non-steroidal antiandrogens Leukopenia, neutropenia Undesirable effects –
Olmesartan Sprue-like enteropathy: In addition to the small intestine, other sections of the gastrointestinal tract can be affected by changes, for example in the form of colitis (including microscopic colitis). Warnings and precautions –
Peanut allergens (Arachis hypogaea) Oral inflammation or lesions: Increased risk of severe systemic allergic reactions in patients with acute severe oral or oesophageal inflammation or oral lesions; delay start of treatment or temporarily interrupt ongoing treatment until healed. Warnings and precautions –
Peanut allergens (Arachis hypogaea) Chronic urticaria can falsify the safety assessment of the treatment. Warnings and precautions –
Peanut allergens (Arachis hypogaea) Hypersensitivity Undesirable effects –
SGLT2 inhibitors Fournier’s gangrene Warnings and precautions –
Trametinib Potentiation of radiation damage Warnings and precautions; Undesirable effects –
Velmanase alfa Infusion-related reactions: apathy, hypotonia, pallor Undesirable effects –